Amylin (AMLN) Attracting a Host of Other Suitors, Shares Rise
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Shares of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) are 5 percent higher early Tuesday following reports indicating Bristol-Myers Squibb (NYSE: BMY) is not the only company interested in the diabetes drugs maker.
Amylin has signed confidentiality agreements Pfizer Inc. (NYSE: PFE), AstraZeneca Plc (NYSE: AZN), Sanofi (NYSE: SNY) Merck & Co. (NYSE: MRK), Takeda Pharmaceutical Co., Roche Holding AG, in addition to Bristol-Myers, Bloomberg reported, citing people familiar with the matter.
First-round bids are due in the next two weeks, the report said.
In March, Amylin rejected a $22 per share bid from Bristol-Myers. Since, share have climbed to nearly $27 per share.
Amylin has signed confidentiality agreements Pfizer Inc. (NYSE: PFE), AstraZeneca Plc (NYSE: AZN), Sanofi (NYSE: SNY) Merck & Co. (NYSE: MRK), Takeda Pharmaceutical Co., Roche Holding AG, in addition to Bristol-Myers, Bloomberg reported, citing people familiar with the matter.
First-round bids are due in the next two weeks, the report said.
In March, Amylin rejected a $22 per share bid from Bristol-Myers. Since, share have climbed to nearly $27 per share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Evolution Petroleum closes $16M Midland Basin royalty acquisition
- Treasure Global sells shares in two deals worth $6.6M total
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
